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Abstract
Background Biopsy of the prostate for suspected cancer is usually performed transrectally under local anaesthesia in the 
outpatient clinic setting. As this involves piercing the bowel wall, the procedure is associated with a risk of infection. 
Recently, devices that facilitate transperineal biopsy approaches have been developed that avoid piercing the bowel and so 
should reduce the risk of infection.
Objective The aim of this study was to estimate the cost effectiveness of transperineal versus transrectal ultrasound-guided 
local anaesthesia procedures for prostate biopsy from the perspective of the UK NHS and to estimate the value of further 
research in the area.
Methods a) Decision tree and Markov model synthesising all relevant evidence estimating the life-time costs and QALYs 
accrued from each biopsy mode. b) Value of information analysis to predict the return from further research and thus guide 
future research efforts.
Results Transperineal biopsy yields an ICER below £20,000 per QALY gained at a per-procedure device acquisition cost 
below £81, or £41 for cost-neutrality. These results are driven by differences in consumables cost, reduced cost of treating 
infections, and QALY gains associated with reduced infections. There is value in future research on the diagnostic accuracy 
of transperineal versus transrectal biopsies and the incidence of iatrogenic infection and sepsis; consideration should be 
given to enriching the patient population with men with intermediate-risk disease.
Conclusions Transperineal biopsy devices may be cost effective compared with transrectal biopsy at per-procedure acquisi-
tion costs below £81 and cost-neutral if under £41. Future research is required to confirm or refute these findings, particularly 
randomised comparisons of the diagnostic accuracy and infection risks between the methods.
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1 Introduction
Prostate cancer is the fourth most common cancer globally, 
with an estimated 1.8 m cases world-wide in 2018 [1] and 
48,500 cases in the UK every year [2]. Current practice 
Key Points for Decision Makers 
Subject to a number of assumptions and based on current 
information, we estimate that transperineal biopsies are 
cost effective compared with transrectal as long as the 
per-procedure acquisition cost is below £81.
Future research should focus on comparative diagnostic 
accuracy and infection risk, focusing particularly on men 
with intermediate-risk disease.
for the diagnosis of prostate cancer is for referred men to 
undergo a multiparametric MRI scan, followed by a tran-
srectal ultrasound-guided biopsy (TRUSBx) [3]. However 
TRUSBx is not without risk, with an incidence of sepsis of 
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sufficiently raised and concerning [8], patients are referred to 
secondary care. Current (2019) NICE guidance [3] recom-
mends multiparametric MRI (mpMRI) as first-line inves-
tigation of men with suspected localised prostate cancer. 
Results are reported on a five-point Likert scale (PI-RADS 
score); those scoring 3 or more are recommended biopsy 
(TRUSBx) using the results of the MRI to inform placing 
of the needle. Those scoring 1 or 2 may omit a biopsy, or be 
offered systemic prostate biopsy (i.e. sampling a wide area 
of the prostate rather than focusing on anomalies identified 
in the MRI scan).
For those with MRI Likert of ≥ 3 but a negative biopsy, 
repeat biopsy might be considered. For those with a raised 
PSA but MRI Likert of 1 or 2 who have not had a biopsy, 
or for whom the biopsy was negative, the PSA test may be 
repeated at 3–6 months and biopsy offered if there is ongo-
ing strong suspicion of cancer. Alternatively, the patient can 
be discharged to primary care with referral if pre-determined 
PSA thresholds are reached. Treatment options for localised 
cancer include active surveillance, radical prostatectomy or 
radical radiotherapy depending on prognosis.
Much of the current NICE guidance on the appropriate 
diagnostic pathway is based on a recent decision model com-
paring many permutations of testing strategies, comprising 
combinations of one or two TRUSBx or template-guided 
biopsies (under GA), with and without mpMRI (Faria et al. 
[9]). This model itself draws on data from a large trial of 
MRI imaging and biopsy in diagnosing prostate cancer (the 
diagnostic Prostate MR Imaging Study, PROMIS [10]), inter 
alia. The cost-effective pathway is mpMRI first line, fol-
lowed by mpMRI-guided TRUSBx where clinically signifi-
cant cancer is suspected, followed by a second TRUSBx if 
the first is negative (strategy ‘M7’ of Faria et al. [9]).
2.2  Modelled Clinical Diagnostic Pathway 
and Structure
In this analysis, we replicated strategy M7 as modelled by 
Faria et al. [9], but added TPUSBx as a comparator strat-
egy in place of TRUSBx, and included the cost and conse-
quences of adverse events such as fever and sepsis associated 
with TRUSBx (Fig. 1). Entry point into the model is referral 
to secondary care. In the TRUSBx arm (status quo), a man 
referred has a probability of having either clinically signifi-
cant cancer (which is defined as either high or intermediate 
risk), clinically non-significant cancer or no cancer, accord-
ing to the prevalence in the referred population. Firstline 
diagnostic is mpMRI, the results of which are either nega-
tive (i.e. no cancer), clinically non-significant or clinically 
significant.
A man with an mpMRI result of no cancer or clinically 
non-significant cancer is discharged to routine follow-up and 
exits the model. A man diagnosed with clinically significant 
around 1%, and other less serious complications occurring 
with greater frequency [3]. The cause of infection is most 
likely due to piercing of the bowel wall with the biopsy 
needle, before insertion into the prostate to retrieve the 
sample. To address this, there has been a move to perform 
prostate biopsies using the much more sterile transperineal 
route [4]. These ‘template biopsies’ (making use of a grid 
placed over the perineum to guide needle insertion points) 
usually necessitate general anaesthesia (GA) with signifi-
cant attendant costs. To overcome this, devices have been 
developed to permit transperineal biopsies (TPUSBx) to 
be performed under local anaesthesia (LA) and hence be 
more suited to the outpatient clinic setting [5–7]. To date 
however, it is not known how cost effective these devices 
are, especially given the relatively low cost and wide avail-
ability of the transrectal biopsy method.
Here we investigated the cost effectiveness of TPUSBx 
devices compared with TRUSBx in the diagnosis of prostate 
cancer in a UK secondary care setting from the perspective 
of the UK National Health Service (NHS). As a case study, 
we used the novel Cambridge Prostate Biopsy (CamPROBE) 
device, which has been recently evaluated for clinical effec-
tiveness and safety [7]. The CamPROBE is based on the 
concept of a co-axial cannula, but designed specifically for 
transperineal prostate biopsies under LA. The device and 
how it is used can be seen at https:// www. youtu be. com/ 
watch?v= Q3XYL q5po8 s&t= 196s. Although we have used 
this device in this analysis, our findings should be broadly 
transferable to any TPUSBx device.
2  Method
We developed a decision model comprising a decision tree 
with Markov models at the terminal nodes. Data inform-
ing the decision model were taken from a prospective case 
series representing the first rigorous data on the safety 
and acceptability of the CamPROBE [7], and other data 
from the literature to inform the likely cost effectiveness 
of the device, at various price points. We also conducted 
a value of information analysis (VoI) to guide the direc-
tion of further research to reduce uncertainty as to the cost 
effectiveness of TPUSBx devices.
The design of the model mirrors the clinical diagnostic 
pathway (described below) to compare the expected lifetime 
costs and QALYs accrued with TPUSBx and TRUSBx.
2.1  Clinical Diagnostic Pathway: Current 
Management
Men presenting in primary care for suspected prostate cancer 
are typically offered a prostate-specific antigen (PSA) test. If 
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cancer by mpMRI undergoes transrectal ultrasound-guided 
biopsy (TRUSBx), with an associated risk of fever, urinary 
tract infection (UTI), sepsis (with risk of death), or no infec-
tion. As per mpMRI, the result of the TRUSBx can be either 
no cancer, clinically non-significant or clinically significant. 
A man with a clinically significant TRUSBx result enters 
the treatment pathway, whilst a man with clinically non-
significant or no cancer is given a repeat TRUSBx (with 
TRUSB2(CS) | TRUSB1(CNS), mpMRI(CS)
treat
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Fig. 1  Decision tree structure. CNS clinically non-significant, CS 
clinically significant, HR high risk, IR intermediate risk, mpMRI 
multi-parametric magnetic resonance imaging, NC no cancer, 
TPUSBx transperineal ultrasound-guided biopsy, TRUSBx transrectal 
ultrasound-guided biopsy, UTI urinary tract infection
 E. C. F. Wilson et al.
associated infection risks), for which the results can again be 
no cancer, clinically non-significant or clinically significant.
A man with a positive mpMRI followed by two negative 
biopsies (either no cancer or clinically non-significant) is 
discharged to routine follow-up and exits the model. A man 
with a positive mpMRI, a negative first biopsy (no cancer 
or clinically non-significant), and a positive second biopsy 
enters the treatment pathway.
The structure of the model is identical for a man pre-
senting with high, intermediate, low risk or no cancer, but 
the conditional probabilities (e.g. diagnostic accuracy of 
TRUSBx) and long-term cost and consequences vary (long-
term model described below). Likewise, the structure of the 
model for the TPUSBx arm is identical, except populated 
with different probabilities of infection and procedure cost 
(see model inputs below and Table 1).
Long-term costs and outcomes were calculated from 
Markov models appended to the terminal nodes dividing 
disease into ‘progression free’, ‘metastatic disease’ and dead 
(Fig. 2). Transition probabilities, costs and health state utili-
ties were assigned from the literature (Table 1), with a transi-
tion period of 1 year. Six possible scenarios were estimated, 
dependent on the true state of the disease and the subsequent 
treatment strategy. For men with no cancer, no further moni-
toring was assumed, and lifetime QALYs calculated based 
on UK lifetable statistics (scenario ‘no cancer’). For men 
diagnosed with clinically non-significant cancer, a strategy 
of active surveillance was assumed, comprising one urology 
follow-up appointment and three PSA tests per annum (sce-
nario ‘clinically non-significant’). Transition probabilities 
reflected the possibility of this becoming metastatic disease 
in the future (intermediate cancer stages are not explicitly 
modelled). For men with intermediate-risk and high-risk 
disease, the treatment strategy could be either active sur-
veillance or radical prostatectomy (scenarios ‘intermediate-
risk active surveillance’, ‘intermediate-risk radical prostatec-
tomy’, ‘high-risk active surveillance’ and ‘high-risk radical 
prostatectomy’).
The relevant scenario lifetime costs and outcomes were 
appended to the terminal nodes of the decision tree: patients 
with no cancer were discharged back to primary care (sce-
nario ‘no cancer’). Patients with clinically non-significant 
cancer were assigned to the active surveillance strategy 
(scenario ‘clinically non-significant’). Patients with cor-
rectly identified intermediate- and high-risk cancers were 
assigned to the respective radical prostatectomy strategy 
(‘intermediate-risk radical prostatectomy’ or ‘high-risk radi-
cal prostatectomy’ scenarios); and those whose cancers were 
misdiagnosed as clinically non-significant or no cancer were 
assigned to the intermediate- and high-risk active surveil-
lance strategy/scenarios, respectively.
2.3  Model Inputs
Chance node probabilities and associated hyperparameters 
as well as health state utilities were replicated from the same 
sources as Faria et al. [9] (see Table 1). Key inputs included 
the sensitivity and specificity of mpMRI and first and second 
TRUSBx, which were extracted from the PROMIS study 
[10] (published 2017) and a 2015 systematic review [11]. 
These data suggested the sensitivity of both mpMRI and 
TRUSBx is 1 in the presence of high-risk cancer; that is, a 
high-risk cancer will never be misdiagnosed, whilst diagno-
sis of clinically non-significant cancer and intermediate-risk 
cancer carries a risk of misdiagnosis as per Table 1. After 
Faria et al. [9], we assumed perfect specificity of TRUSBx 
(i.e. a patient with no cancer will always be correctly diag-
nosed), but imperfect sensitivity as per Table 1. Dirichlet, 
Connor-Mosimann or modified Connor-Mosimann distribu-
tions were fitted [12] to the summary statistics reported in 
Faria et al. [9], which were then inserted into the model 
(see Appendix 1 in the Electronic Supplementary Material 
[ESM]). Note, as there are three possible outcomes from 
the biopsy (no cancer, clinically non-significant or clinically 
significant), there is no single measure of ‘sensitivity’ or 
‘specificity’ as such, but probabilities of one of the three 
results, conditional on the true disease state. From hereon 
we refer to these measures as ‘diagnostic accuracy’.
We assigned the same probability distributions to the 
TPUSBx diagnostic accuracy as TRUSBx. The implied 
assumption of this is that on average we expect there to be 
no difference between the two methods in these parameters, 
but as the distributions are modelled independently, the sen-
sitivity and specificity can each vary according to current 
levels of uncertainty.
The risk of infection associated with TRUSBx was 
extracted from the treatment arm of a Cochrane systematic 
review of the effects of antibiotic prophylaxis for TRUSBx 
[13], and mortality from sepsis was estimated [14] from US 
Surveillance, Epidemiology and End Results (SEER) data 
[15]. Our base case assumed a zero risk of infection asso-
ciated with TPUSBx. This was based on the prospective 
case series of 40 TPUSBxs from the recent CamPROBE 
published results [7].
To estimate long-term model transition probabilities, para-
metric distributions were fitted [12] to the summary statistics 
reported in Faria et al. [9] (see Appendix 1 in the ESM). Incidence 
of adverse events following radical prostatectomy and active sur-
veillance were extracted from a randomised controlled trial (RCT) 
of the two modalities [16], converted to 1-year probabilities.
Unit costs were extracted from routine NHS unit cost 
sources [17–19] for the price year 2018–19. The unit cost 
of the TPUSBx and TRUSBx procedures was based on a 
microcosting exercise (Appendices 2 and 3, see ESM). As 
this is a small sample from one centre only and the price of 







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Economic Evaluation of TP vs TR Prostate Biopsies
the TPUSBx device itself is unknown, our base-case analysis 
assumes equal procedure time and a zero price for the TPUSBx 
device: We explore the various price points in sensitivity anal-
ysis. Other cost inputs were based on previously described 
treatment regimens [20]. Health state utilities were extracted 
from relevant previous reports and sources [9, 21] (Table 1).
2.4  Analysis
The model and inputs were reviewed for face validity and 
clinical plausibility by the clinical lead (VG). Internal valid-
ity checks were conducted to test for bugs and errors (details 
and model code available from corresponding author). Anal-
ysis was based on a 50-year-old male and run for 30 years, 
representing the expected life span of the individual. Future 
costs and QALYs were discounted at the UK recommended 
rate of 3.5% [22]. Analysis was conducted probabilistically 
via Monte Carlo simulation, repeatedly running the model 
with sets of inputs drawn from their respective distribu-
tions. Stability testing determined the appropriate number 
of simulations, with a coefficient of variation of estimates 
of (a) mean incremental net benefit and (b) standard error 
of mean incremental net benefit below 2% declared stable.
We reported mean cost and QALYs associated with 
TRUSBx and TPUSBx, increments and 95% credibility 
intervals, incremental cost-effectiveness ratios and incre-
mental net benefit (INB) at a threshold of £20,000 per 
QALY. As no price is currently set for the model TPUSBx 
device (CamPROBE), our base case assumes a zero price, 
and we draw readers’ attention to our sensitivity analyses:
1. We present a one-way sensitivity analysis on the price 
of the TPUSBx device, identifying the price associated 
with an ICER of £20,000.
2. Our base case assumes the risk of infection with 
TPUSBx is zero, thus we present a one-way sensitivity 
analysis on risk of infection with TPUSBx, varying the 
risk between 0 and 100% of that of TRUSBx. The base-
case price for CamPROBE is assumed in this analysis.
3. As the reduction in risk of infection is considered the 
primary benefit of TPUSBx, we present a two-way sen-
sitivity analysis showing the maximum cost-effective 
per-procedure price of the TPUSBx device as a function 
of the infection risk.
Finally, we present a VoI, estimating the expected value 
of perfect information (EVPI) and expected value of perfect 
parameter information (EVPPI) to help guide future research 
efforts to where they will be of most value. VoI parameters 
are calculated for the relevant patient population of Eng-
land over a time horizon of 10 years (337,516; Appendix 4, 
see ESM). As the value for further information is depend-
ent on the point estimate cost effectiveness, which itself is 
dependent on the price of the TPUSBx device, we present 
two analyses: one at the base case zero price and one at the 






Fig. 2  Long-term model structure
Table 2  Point estimate cost effectiveness at equal procedure cost, and maximum cost-effective per-procedure price for TPUSBx device, mean 
(95% credible interval [CrI])
ICER incremental cost-effectiveness ratio, INB incremental net benefit, P(CE) Probability ICER is below £20,000 per QALY, TPUSBx transper-
ineal ultrasound-guided biopsy, TRUSBx transrectal ultrasound-guided biopsy
*Calculated at £20,000 per QALY
**TPUSBx dominates TRUSBx
***Price of TPUSBx device rounded to the nearest 1p, hence ICER is slightly below £20,000 and INB slightly above £0
Intervention Cost (£) QALYs Net benefit (£)* ICER P(CE) (%)
TRUSBx 5051.52 (4518.29–5593.38) 10.291 (9.909–10.671) 200,762.00 (193,082.06–208,393.78)
Zero price of TPUSBx device
 TPUSBx 5021.91 (4489.16–5560.88) 10.292 (9.911–10.672) 200,820.90 (193,140.36–208,448.03)
 Increment − 29.61 (− 501.54 to 441.68) 0.0015 (− 0.081 to 0.084) 58.88 (− 1192.63 to 1322.16) Dominant** 59
Max price of TPUSBx device (£81.17)
 TPUSBx 5080.79 10.292 200,758.70 (193,080.17 to 208,389.23)
 Increment 29.27 (− 442.72 to 500.51) 0.0015 (− 0.081 to 0.084) 0.0012*** (− 1251.59 to 1262.89) £19,999*** 50
 E. C. F. Wilson et al.
ICER is £20,000/expected INB is £0 and so decision uncer-
tainty is maximised. This thus represents an absolute upper 
bound to the value of further information.
3  Results
Stability testing suggested that 200,000 iterations were suf-
ficient for purpose (Appendix 5, see ESM).
At a zero price of the TPUSBx device, there is a 59% 
probability that it is cost effective compared with TRUSBx 
(Table 2 and Appendix 6, Table A6.1 [see ESM]). The cost-
neutral per-procedure price (i.e. the price yielding a zero 
incremental cost) is £40.82. The maximum cost-effective 
price (yielding an ICER of £20,000 per QALY) is £81.17 
(Fig. 3a). At this price there is a 50% probability of cost 
effectiveness. Note, this is the per-procedure price; thus, for 
the example of CamPROBE where two devices are required, 
the maximum cost effective price is £40.59.
The above prices assume a zero infection risk with 
TPUSBx. As the risk of infection approaches that of 
TRUSBx, the maximum per-procedure cost-effective price 
falls to approximately £14.50 (Fig. 3b).
Value of information analysis suggests the overall 
value of eliminating all decision uncertainty is worth 
between £56 m and £65 m to the population of England, 
depending on the price of TPUSBx (Fig. 4 and Appen-
dix 6, Tables A6.2–A6.4, see ESM). This is particularly 
focused on the diagnostic accuracy of a second transper-
ineal or transrectal biopsy following a first biopsy result 
of ‘clinically non-significant cancer’, when the true dis-
ease state is intermediate-risk cancer (group EVPPI £46.2 
m to £54.7 m, depending on the price of TPUSBx). There 
may also be value in reducing uncertainty in the probabil-
ity of infection with TRUSBx (up to £5.0 m), long-term 
prognosis (£4.4 m) and the diagnostic accuracy of biopsy 
in patients with a true disease state of anything other than 
no cancer (between £1.8 m and £3.2 m each). However, 
this is only true when the price for CamPROBE is towards 
the upper end of its maximum cost-effective price; at a 
lower price for CamPROBE, there is minimal value in 
reducing uncertainty in these parameters.
4  Discussion
4.1  Interpretation of Results
Given current information, a per-procedure price for a 
TPUSBx device of up to £81.17 is expected to yield an 
incremental cost-effectiveness ratio at or below £20,000 per 
QALY gained. This price is derived from both the differ-
ences in consumables required between the procedures and 
Fig. 3  Sensitivity analyses on a price and b price vs risk of infection. 
a INB vs per-procedure price. Price expressed as per procedure price 
of TPUSBx, not per unit (e.g. if two units required, then the unit price 
is half that stated). Data reported in Appendix 6, Table A6.1 (see ESM). 
b Maximum cost-effective price vs risk of infection. Shading shows INB; 
lighter shading indicates higher INB. Solid line shows locus of points 
yielding an INB of £0 (= ICER of £20,000), and thus shows the maxi-
mum cost-effective price as a function of the infection risk. Risk of infec-
tion is expressed as a proportion of the risk associated with TRUSBx (i.e. 
relative risk, so risk = 1 means same probability of infection, risk = 0.5 
means 50% probability of infection). Price is expressed as per procedure 
price; thus, if TPUSBx requires 2 units, the max unit cost is half the stated 
price. Points to the south-west of the line yield an INB > £0 (ICER < 
£20,000), those to the north-east yield an INB < £0 (ICER > £20,000). 
One-way sensitivity analysis against risk of infection alone is shown in 
Appendix 6, Fig A6.2 (see ESM). INB incremental net benefit, ESM elec-
tronic supplementary material, ICER incremental cost-effectiveness ratio, 
TPUSBx transperineal ultrasound-guided biopsy, TRUSBx transrectal 
ultrasound-guided biopsy
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the assumed elimination of risk of infection associated with 
TRUSBx, which both averts loss of QALYs and reduces 
health system cost. We also assumed that on average, 
TRUSBx and TPUSBx had the same diagnostic accuracy.
At this maximum price, decision uncertainty is also max-
imised, with a 50% probability that TPUSBx is cost effec-
tive. At a zero price, there is a 59% probability of TPUSBx 
being cost effective. This decision uncertainty is reflected in 
an EVPI of £56 m or £65 m (at zero or £81.17 per-procedure 
price, respectively). This represents the opportunity loss due 
to uncertainty and can be equally expressed as 2818 or 3271 
QALYs foregone to patients in England.
The interpretation of this result is that at or below the 
maximum price, TPUSBx is on average the cost-effective 
option, but this is uncertain, and if wrong there is a loss to 
society in terms of foregone health gain: either a TRUSBx 
would have been better for diagnosing prostate cancer or 
TPUSBx is overpriced leading to a net loss of health gain as 
excessive resources are diverted to TPUSBx. The probability 
of being wrong (incurring an opportunity loss) is around 
41% (50% at maximum price). So, in 41 (50) of 100 possible 
realisations of the world, TPUSBx is not cost effective. The 
expected loss due to uncertainty (= 41% * loss or = 50% * 
loss) is around 2818 (3271) QALYs, or £56 m (£65 m) when 
each QALY is valued at £20,000. This represents the maxi-
mum amount that should be paid for research to eliminate 
uncertainty. At the cost-neutral price of £40.82, the EVPI is 
£61 m, or 3034 QALYs.
Exploring further, the parameters responsible for the 
greatest opportunity loss due to uncertainty are those relat-
ing to the diagnostic accuracy of a second biopsy (whether 
TP or TR), following a first biopsy result of clinically non-
significant cancer, when the true health state is intermediate-
risk cancer (EVPPI = £46m or £55m, accounting for 82% or 
84% of the entire EVPI, Appendix 6, Table A6.2, see ESM). 
There is also some value in reducing uncertainty in the prob-
ability of infection with TRUSBx, long-term prognosis from 
different management strategies, and diagnostic accuracy 
of the entire biopsy pathway (both first and second biopsy) 
in patients with a true state of high-risk cancer or clinically 
non-significant cancer.
These recommendations for research are for very specific 
subpopulations of those men undergoing prostate biopsy 
and must be considered within the context of the overall 
assumptions of the model. In our base case we assumed (1) 
a zero risk of infection with TPUSBx, (2) on average equal 
sensitivity and specificity between TRUSBx and TPUSBx, 
(3) perfect specificity and (4) perfect sensitivity in high risk 
disease. Whilst recent systematic reviews do not contradict 
these assumptions [23, 24] (see Sect. 4.3), this may not 
always be the case in every-day practice. The EVPPI of £46 
m to £55 m represents the upper limit for a trial budget that 
would eliminate uncertainty. A trial of finite sample size can 
only reduce, and not eliminate uncertainty, so the expected 
value of sample information (EVSI), which is a function of 
the sample size, will be lower than this. Calculation of EVSI 
is extremely computationally expensive. Several statistical 
approximation methods are available [25], but unfortunately 
due to the nature of our data we were unable to generate 
solutions to the EVSI parameters.
Taking the EVPPI results, sensitivity analyses and 
base-case assumptions into account, a suitably powered 
comparative study of the risk of infection and diagnostic 
accuracy associated with TRUSBx devices versus TPUSBx 
may be warranted. Diagnostic accuracy can be established 
with patients acting as their own controls and/or in those 
whose disease status is already known, if they are willing 
to undergo both procedures, whereas establishing risk of 
infection may require an RCT design. Consideration should 
be given to enriching the enrolled population in these studies 
with men with a diagnosis of, or high prior probability of 
intermediate-risk cancer.
4.2  Strengths and Weaknesses
Our analysis presents a synthesis of current evidence on 
the cost and consequences of transperineal in place of tran-
srectal ultrasound-guided biopsy in the diagnosis of cancer 
of the prostate. The conduct and reporting of our analysis 
conforms to best practice in economic evaluation [22, 26]. 
However, there are a number of limitations.
Any decision model is only as reliable as its assumptions. 
Our estimate of the maximum price is based on differences 
in consumables cost and elimination of infection risk. The 
quality of the data (reflecting the stage of development of 
the model device) must be considered when addressing the 
generalisability of our results. For example, the observed 
difference in consumables cost is driven by replacing the 
transrectal biopsy needle and guide with the CamPROBE 
device and based on a small sample of biopsies conducted 
in one centre (a large research-intensive teaching hospital). 
Consideration must be given as to whether this is generalis-
able to other settings; we provide full microcosting data in 
Appendix 2 to assist this (see ESM).
The other major component of value is the reduction in 
biopsy-associated infection. Indeed, this is the major anticipated 
benefit. Whilst we feel the estimates of QALY loss and health 
service cost associated with infections are plausible, the biggest 
uncertainty is the probability of infection itself. Data and budget-
ary limitations prevented us from assigning a plausible probabil-
ity distribution for this (e.g. by conducting a formal expert elici-
tation process), so we addressed this by conducting a two-way 
sensitivity analysis, showing the maximum price as a function of 
the risk of infection, but stress the need for good quality compara-
tive data to establish the difference in infection rate.
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We also assumed an on-average equal diagnostic accuracy 
for transrectal and transperineal biopsies. We conducted an 
additional one-way sensitivity analysis on the probability of 
a true positive in patients with intermediate-risk cancer, con-
cluding that transperineal biopsies remained cost effective 
as long as the relative probability was at least 98.8–99.97% 
that of transrectal, depending on the price of the transper-
ineal biopsy device, with a higher price giving less ‘room’ 
for a reduction in relative diagnostic accuracy (Appendix 6, 
Tables A6.6 and A6.7, see ESM). Note, the figures quoted 
above are for the relative true-positive rate, not the absolute.
Finally, we did not include any costs for training or the 
impact of any learning curve effect in the analysis. In the 
experience of our clinical lead (and inventor of CamPROBE, 
VG), transferring from transrectal to transperineal biopsies 
is relatively straightforward with minimal training require-
ments. So whilst our analysis could be regarded as a ‘steady 
state’, assuming surgeons are fully competent in the trans-
perineal technique, any additional training costs should be 
minor.
4.3  Comparison with Other Studies
We are not aware of any other economic evaluations com-
paring the cost effectiveness of transrectal and transperineal 
ultrasound-guided devices for local anaesthetic biopsies. 
Several transperineal biopsy devices have recently entered 
the market; a 2020 systematic review [23] comparing tran-
srectal and transperineal methods identified 14 studies 
enrolling approximately 2000 patients. However, all but one 
 
*Assuming maximum cost-effecve price for CamPROBE (£81.17).  Figure shows EVPI and EVPPI associated with 
various groups of parameters. TR = transrectal; TP = transperineal; IR = intermediate risk; NC = no cancer; HR = 














































































































































































































































































































































































































































Fig. 4  Expected value of perfect (parameter) information (EVPPI) 
to England, assuming maximum cost-effective price for CamPROBE 
(£81.17). Figure shows EVPI and EVPPI associated with various 
groups of parameters. CaP cancer of the prostate, CNS clinically 
non-significant, HR high risk, IR intermediate risk, NC no cancer, TP 
transperineal, TR transrectal
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of these were single-arm cohort studies. The one compara-
tive study compared both techniques in the same patients 
[27]. The review concluded that both techniques were of 
similar sensitivity and specificity, although the diagnostic 
odds ratio may favour the transrectal approach [23]. Another 
(2019) systematic review [24] identified four RCTs (and a 
number of observational studies), concluding there was 
no evidence of a difference between transrectal and trans-
perineal biopsies, although this review did not distinguish 
between GA-based template and non-template LA trans-
perineal biopsy and did not explore sensitivity and speci-
ficity, instead reporting the ratio of cancer detection rates. 
However, the authors noted that TPUSBx was associated 
with a lower risk of fever and rectal bleeding. High-quality 
comparative data specifically comparing infection rates with 
the two techniques are somewhat limited, although a number 
of smaller single-centre and retrospective database analyses 
suggest an effective zero rate of sepsis with transperineal 
biopsy [4, 28–32].
The most influential economic study on UK prostate 
biopsy policy is the Faria et al. [9] model, drawing on the 
PROMIS study [10], on which UK guidelines are largely 
based. Other economic studies support the use of mpMRI 
first line [33–36] and newer biomarker tests appear cost 
effective compared with a first-line biopsy [37, 38]. How-
ever, comparison with mpMRI first line is unknown.
5  Conclusion
Transperineal ultrasound-guided biopsies have the potential 
to be cost effective with a device priced at up to £81.17 
per procedure. This price must be divided by the number 
of units required per procedure to obtain the maximum unit 
price: if two devices are used, this equates to £40.59 per unit. 
A cost-neutral price to the NHS is £40.82 per procedure. 
The greatest value of further research is in the diagnostic 
accuracy of TPUSBx versus traditional transrectal prostate 
biopsy, and in the risk of infection associated with the two 
biopsy modes. Consideration should be given to enriching 
the enrolled patient population with men with either known 
or a high prior probability of intermediate-risk disease. New 
biomarkers are showing potential to assist in the diagnosis 
of prostate cancer, which may change the prevalence of dis-
ease in those eventually referred for biopsy, and hence the 
cost effectiveness of different diagnostic pathways. Future 
economic modelling aimed at informing the next revision 
of guidelines and clinical pathways should consider both 
(non-template) transperineal biopsy procedures as well as 
biomarker tests.
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